Results 21 to 30 of about 2,234,624 (258)

Phosphorylation of KIAA1429 promotes oxaliplatin resistance through activating the FZD7-Wnt signaling in BRAFV600E-mutated colorectal cancer [PDF]

Journal of Experimental & Clinical Cancer Research
Background The current standard therapeutic approach for colorectal cancer (CRC) is surgical operation and oxaliplatin (OXA)-based neoadjuvant chemotherapy.
Taixuan Wan, Minyi He, Zhanzhen Liu, Yihang Zhou, Yebohao Zhou, Wei Xiao, Hao Xie, Shuangling Luo, Haoqi Zheng, Liang Kang, Yunxing Shi, Liang Huang   +11 more
doaj   +2 more sources

USF1-activated hsa_circ_0076691 induces oxaliplatin resistance via facilitating FGF9 expression in miR-589-3p-dependent manners [PDF]

Non-coding RNA Research
Chemotherapeutic efficacy in colorectal cancer (CRC) is significantly hindered by the development of drug resistance. Emerging evidence indicates that circular RNAs (circRNAs) play pivotal roles in various cancer-related biological processes. Nonetheless,
Lingyu Tang, Xuan Deng, Ming Guan, Liang Zhong   +3 more
doaj   +2 more sources

Oxaliplatin-resistant colorectal cancer models for nanoparticle hyperthermia [PDF]

International Journal of Hyperthermia, 2021
Metastatic colorectal cancer (CRC) is complicated by chemotherapy-resistant cell populations. Oxaliplatin is used in heated intraperitoneal hyperthermic chemoperfusion (HIPEC) for treatment of disseminated CRC. Photothermal nanoparticles can provide focal heating to improve the response of CRC cells to oxaliplatin, by confining heating near individual ...
Bryce McCarthy, Ravi Singh, Nicole Levi-Polyachenko   +2 more
openaire   +3 more sources

JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis

Acta Biochimica et Biophysica Sinica, 2023
Currently, platinum-containing regimens are the most commonly used regimens for advanced gastric cancer patients, and chemotherapy resistance is one of the main reasons for treatment failure.
Li Suyao, Wei Yichou, Sun Xun, Liu Mengling, Zhu Mengxuan, Yuan Yitao, Zhang Jiayu, Dong Yu, Hu Keshu, Ma Sining, Zhang Xiuping, Xu Bei, Jiang Hesheng, Gan Lu, Liu Tianshu   +14 more
doaj   +1 more source

KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation

Translational Oncology, 2023
Oxaliplatin is a commonly used platinum drug for colorectal cancer (CRC). However, the treatment of CRC by oxaliplatin usually fails because of drug resistance, which results in a huge challenge in the therapy of CRC.
Qingling Hua, Yuanyuan Lu, Dingxiang Wang, Jie Da, Wanren Peng, Guoping Sun, Kangsheng Gu, Hua Wang, Yanzhe Zhu   +8 more
doaj   +1 more source

Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent Chemotherapy

Pharmaceuticals, 2022
Aberrant expression of genes contributes to the chemoresistance of colorectal cancer (CRC) treatment. This study aimed to identify genes associated with the chemoresistance of oxaliplatin-based chemotherapy in CRC patients and to construct a signature ...
Yixin Yin, Siqi Li, Xinqiang Liang, Kezhi Li, Mingzhi Xie, Bangli Hu   +5 more
doaj   +1 more source

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance [PDF]

Molecular Cancer Therapeutics, 2015
AbstractOxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for treatment failure still is the existence of tumor intrinsic or acquired resistance. Consequently,
Eva, Martinez-Balibrea, Anna, Martínez-Cardús, Alba, Ginés, Vicenç, Ruiz de Porras, Catia, Moutinho, Laura, Layos, José Luis, Manzano, Cristina, Bugés, Sara, Bystrup, Manel, Esteller, Albert, Abad   +10 more
openaire   +4 more sources

LRRC8A promotes the initial development of oxaliplatin resistance in colon cancer cells

Heliyon, 2023
Leucine-rich repeat-containing 8 A (LRRC8A) is an essential component of the volume-regulated anion channel (VRAC), which plays a vital role in cell proliferation, migration, apoptosis, and drug resistance.
Haifeng Zhang, Zhenghui Jing, Rong Liu, Yassin Shada, Sindhwani Shria, Shiyu Cui, Yuhua Ren, Yuan Wei, Liangming Li, Shuang Peng   +9 more
doaj   +1 more source

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer

Cancers, 2022
Resistance to treatments is one of the leading causes of cancer therapy failure. Oxaliplatin is a standard chemotherapy used to treat metastatic colorectal cancer. However, its efficacy is greatly reduced by the development of resistances. In a previous study, we deciphered the mechanisms leading to oxaliplatin resistance and highlighted the roles ...
Chocry, Mathieu, Leloup, Ludovic, Parat, Fabrice, Messé, Mélissa, Pagano, Alessandra, Kovacic, Hervé   +5 more
openaire   +2 more sources

Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer

Signal Transduction and Targeted Therapy, 2022
Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance.
Yimin Li, Yaqi Gan, Jiaxin Liu, Juanni Li, Zhengwei Zhou, Ruotong Tian, Ruizheng Sun, Jiaqi Liu, Qing Xiao, Yuanyuan Li, Pengyan Lu, Yulong Peng, Yuqian Peng, Guang Shu, Gang Yin   +14 more
doaj   +1 more source